Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new pill for enlarged prostate match the original?

NCT ID NCT07722871

Not yet recruiting Disease control Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial is testing whether a new formulation of a drug for benign prostatic hyperplasia (enlarged prostate) works the same as the existing version. Healthy adult male volunteers receive a single dose of each formulation after a meal, and researchers compare how much drug gets into the bloodstream. The goal is to see if the new version can be used as an equivalent alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a new formulation of a drug for benign prostatic hyperplasia (AD-116A) compared to the original (AD-1161)
What this could lead to
If the new formulation is shown to be equivalent, it could offer an alternative treatment option for enlarged prostate.
What could go wrong
This is an early-phase study in healthy volunteers, not patients, so results may not predict real-world effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BENIGN PROSTATIC HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BENIGN PROSTATIC HYPERPLASIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • H PLUS YANGJI HOSPITAL, Seoul

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.